These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 24642342)

  • 1. Development of insulin antibodies and changes in titers over a long-term period in patients with type 2 diabetes.
    Hattori N; Duhita MR; Mukai A; Matsueda M; Shimatsu A
    Clin Chim Acta; 2014 Jun; 433():135-8. PubMed ID: 24642342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical application of the different cross-reactivities of anti-insulin antibodies to insulin lispro to evaluate endogenous insulin secretion.
    Yoshida R; Ohkubo K; Akehi Y; Harada S; Shinohara K; Kawashima H; Ono J; Matsunaga A
    Clin Chim Acta; 2013 Jan; 415():250-4. PubMed ID: 23159841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
    Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
    Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes.
    Tibaldi JM
    Clin Ther; 2011 Nov; 33(11):1630-42. PubMed ID: 22030443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding characteristics and crossreactivity of insulin autoantibodies and insulin antibodies directed to three different insulin molecules.
    Jaeger C; Winter S; Eckhard M; Hardt P; Brendel MD; Bretzel RG
    Acta Diabetol; 2008 Sep; 45(3):191-4. PubMed ID: 18493700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes.
    Luzio SD; Dunseath GJ; Atkinson MD; Owens DR
    Diabetes Metab; 2013 Dec; 39(6):537-42. PubMed ID: 24139704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term glycaemic control with insulin glargine in Type 2 diabetes.
    Kacerovsky-Bielesz G; Dressler A; Freunscht R
    Diabetes Res Clin Pract; 2006 Feb; 71(2):184-91. PubMed ID: 16112241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial.
    Füchtenbusch M; Rabl W; Grassl B; Bachmann W; Standl E; Ziegler AG
    Diabetologia; 1998 May; 41(5):536-41. PubMed ID: 9628270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial.
    Perriello G; Pampanelli S; Porcellati F; Avogaro A; Bosi E; Petrella G; Squatrito S; Furneri S; Marra G; Vitali L; Previti M; Cucinotta D
    Diabet Med; 2005 May; 22(5):606-11. PubMed ID: 15842516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of liraglutide on both hypereosinophilic insulin allergy and the characteristics of anti-insulin antibodies in type 2 diabetes mellitus: a case report.
    Hirai H; Ogata E; Kikuchi N; Kohno T; Machii N; Hasegawa K; Watanabe T; Satoh H
    J Med Case Rep; 2016 Jul; 10():202. PubMed ID: 27456688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological insulin resistance due to insulin antibodies developed after cessation of insulin therapy in a patient with type 2 diabetes.
    Hirano M; Arima H; Oiso Y
    Diabetes Care; 2008 Nov; 31(11):e84. PubMed ID: 18955711
    [No Abstract]   [Full Text] [Related]  

  • 14. [Circulating immune complexes and insulin-binding capacity of the serum of diabetics].
    Vel'bri SK; Lilleorg AL; Kerge IaKh
    Probl Endokrinol (Mosk); 1986; 32(2):25-8. PubMed ID: 3520540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe insulin resistance due to anti-insulin antibodies: response to plasma exchange and immunosuppressive therapy.
    Greenfield JR; Tuthill A; Soos MA; Semple RK; Halsall DJ; Chaudhry A; O'Rahilly S
    Diabet Med; 2009 Jan; 26(1):79-82. PubMed ID: 19125765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-induced skin complication in an anti-insulin antibody positive patient with type 2 diabetes.
    Hamasaki H; Hamasaki Y
    Diabetes Metab Syndr; 2018 Sep; 12(5):829-830. PubMed ID: 29661603
    [No Abstract]   [Full Text] [Related]  

  • 17. The insulin analog aspart: a safe alternative in insulin allergy.
    Airaghi L; Lorini M; Tedeschi A
    Diabetes Care; 2001 Nov; 24(11):2000. PubMed ID: 11679473
    [No Abstract]   [Full Text] [Related]  

  • 18. The effects of anti-insulin antibodies and cross-reactivity with human recombinant insulin analogues in the E170 insulin immunometric assay.
    Kim S; Yun YM; Hur M; Moon HW; Kim JQ
    Korean J Lab Med; 2011 Jan; 31(1):22-9. PubMed ID: 21239867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of non-insulin dependent diabetes mellitus with antiinsulin antibody: effect of subcutaneous injection of human recombinant insulin-like growth factor-I.
    Kajimoto Y; Kawamori R; Fujitani Y; Kishimoto M; Kubota M; Yamasaki Y; Morishima T; Kamada T
    Endocr J; 1995 Feb; 42(1):101-5. PubMed ID: 7599690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of biosynthetic human insulin. Humoral immune response in diabetic patients beginning insulin treatment and in patients previously treated with other insulins.
    Di Mario U; Arduini P; Tiberti C; Lombardi G; Pietravalle P; Andreani D
    Diabetes Res Clin Pract; 1986; 2(6):317-24. PubMed ID: 3545723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.